Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Serrapeptase and Reduced Tissue Stiffness

Doses used in studies

IU/day: 60,000 (median 60,000, IQR 60,000–60,000) — 1 study

Time to effect

Median: 4 weeks · IQR 4 weeks–4 weeks · Range 4 weeks–4 weeks — Reported in 1 of 1 study

Safety in these studies

Overall tolerabilityReported
Serrapeptase was well-tolerated with no adverse events reported.
from: Serrapeptase After Liposuction for Lipedema: Limited Evidence for Antifibrotic Efficacy.

1 of 1 paper

Serrapeptase After Liposuction for Lipedema: Limited Evidence for Antifibrotic Efficacy.
- 2026-02-05
- Observational · n = 25
- Aesthetic plastic surgery 50(9)
- - Agostino Bruno
  - Valerio Saccoccio
- PubMed: 41642311
- DOI: 10.1007/s00266-026-05638-0
4 Insights on
- Reduced Tissue Stiffness
- Low evidence
- Clinical
No statistically significant differences were observed in the primary outcome of tissue stiffness at 4 weeks (14.8 ± 3.1 kPa vs. 15.2 ± 3.0 kPa; p = 0.62) or 3 months (13.7 ± 2.9 kPa vs. 14.0 ± 3.2 kPa; p = 0.78).
Effect
Neutral
Effect size
Small
Significant
No
Dose
60,000 IU daily for 4 weeks